New pill could stop hives from scratching or cold
NCT ID NCT06603220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2a trial tested an oral drug called EVO756 in 30 adults with chronic inducible urticaria, a condition where physical triggers like scratching or cold cause hives. The study aimed to see if the drug is safe and can reduce wheals. Results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EVO756
- What this could lead to
- If successful, EVO756 could offer a new treatment option for people with chronic inducible urticaria, reducing hives triggered by physical stimuli like scratching or cold.
- What could go wrong
- This is a small, early-phase (2a) trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INDUCIBLE URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Clinical Research Institute
Tampa, Florida, 33607, United States
-
Aeroallergy Research Laboratories of Savannah, Inc.
Savannah, Georgia, 31406, United States
-
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania, 15241, United States
-
Allergy, Asthma, and Clinical Research Center
Oklahoma City, Oklahoma, 73120, United States
-
Austin Institute for Clinical Research
Pflugerville, Texas, 78660, United States
-
Bexley Dermatology Research
Bexley, Ohio, 43209, United States
-
Cahaba Dermatology & Skin Health Center, LLC
Birmingham, Alabama, 35244, United States
-
California Allergy and Asthma Medical Group
Los Angeles, California, 90025, United States
-
Chesapeake Clinical Research, Inc
White Marsh, Maryland, 21162, United States
-
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250, United States
-
DelRicht Research
Baton Rouge, Louisiana, 70809, United States
-
Indiana Clinical Trials Center, P.C.
Plainfield, Indiana, 46168, United States
-
Integrative Skin Science and Research
Sacramento, California, 95815, United States
-
OptiSkin Medical
New York, New York, 10128, United States
-
Red River Research Partners
Fargo, North Dakota, 58013, United States
-
Southern Indiana Clinical Trials
New Albany, Indiana, 47150, United States
-
Treasure Valley Medical Research
Boise, Idaho, 83706, United States
-
West Dermatology Research Center
San Diego, California, 92121, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill for chronic hives enters first human safety tests
- New drug shows promise for Long-Term control of chronic hives
- Scientists hunt for clues to better diagnose triggered hives
- New pill could tame stubborn hives
- New shot may stop hives from cold and scratching
- New shot could tame stubborn hives that antihistamines Can't stop